A PET scan (positron emission tomography) is an imaging test that shows how tissues in the body are using energy, highlighting areas of unusually high activity such as cancer. The patient receives a small amount of a radioactive sugar tracer, which cancer cells absorb more than normal cells, making tumors light up on the scan. It is often combined with a CT scan (PET-CT) to show both activity and precise location.
Origin
PET imaging was developed in the 1970s by researchers including Michael Phelps and Edward Hoffman, building on earlier work in nuclear medicine. The technology entered routine cancer care in the 1990s and 2000s.
Significance in Asbestos Context
For mesothelioma and asbestos-related lung cancer, a PET scan helps doctors see how far the disease has spread and whether lymph nodes or distant sites are involved, which is central to staging and to deciding whether surgery is an option. It can also help tell active tumor from scar tissue and track how well treatment is working. Results aren't perfect; inflammation and infection can also light up, and mesothelioma's thin, spreading growth can be hard to capture, so PET is used alongside CT, MRI, and biopsy. The staging information from these scans often appears in both your medical planning and your legal case.
Example Sentence
His PET-CT scan showed the mesothelioma had spread to nearby lymph nodes, which ruled out the aggressive surgery his team had considered.
Related Terms
CT Scan, Staging, Mesothelioma, Metastasis, MRI, Biopsy
Notes
- Ask whether a PET-CT (combined scan) is appropriate, since it pairs metabolic activity with precise anatomy for staging.
- Request copies of your imaging and the radiologist's reports, which document the disease's extent for both treatment and any claim.
- Understand that PET findings guide but don't replace biopsy; tissue confirmation is still needed to establish the diagnosis.
In the research library
20 studies in our medical research library mention PET Scan in the title or abstract. Among the most cited:
- PET scan contribution in chest tumor management: a systematic review for thoracic surgeonsL. Duranti, F. Leo, U. Pastorino, 2012 · Tumori · cited 6 times
- Central photopenic lesions on FDG-PET scan in a patient with peripheral T cell lymphomaA. Mavi, T. Dhuriraj, T.F. Cermik, et al, 2008 · Annals of Nuclear Medicine · cited 2 times
- A Phase I Trial of Regional Mesothelin-Targeted CAR T-cell Therapy in Patients with Malignant Pleural Disease, in Combination with the Anti-PD-1 Agent PembrolizumabP.S. Adusumilli, M.G. Zauderer, I. Rivière, et al, 2021 · Cancer Discovery · cited 537 times
- Do high glucose levels have differential effect on FDG uptake in inflammatory and malignant disorders?H.M. Zhuang, A. Cortés-Blanco, M. Pourdehnad, et al, 2001 · Nuclear Medicine Communications · cited 79 times
- Role of integrated 18-fluorodeoxyglucose position emission tomography-computed tomography in patients surveillance after multimodality therapy of malignant pleural mesotheliomaC. Tan, S. Barrington, S. Rankin, et al, 2010 · Journal of Thoracic Oncology · cited 29 times
The journals that publish most on it: Respiratory Medicine Case Reports (3), Journal of Gastrointestinal Surgery (1), Journal of Thoracic Oncology (1).
Category: Diagnostic Tools & Biomarkers · All Lexicon terms A–Z
This page is provided for general informational purposes and does not constitute legal advice. Every asbestos case turns on its own facts, exposure history, diagnosis, deadlines, available evidence, and applicable law. Reviewing this page does not create an attorney-client relationship. For advice about your specific situation, call 833-4-ASBESTOS for a free case review.